Founded in 2015, Oricell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.
Location: China, Shanghai, Pudong
Employees: 51-200
Total raised: $45M
Investors 1
| Date | Name | Website |
| 06.01.2024 | Qiming Ven... | qimingvc.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.02.2023 | Series B | $45M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 29.01.2024 | Oricell Announces FDA Clearance of IND Application for OriCA... | SHANGHAI and ROSELAND, N.J., Jan. 29, 2024 /PRNewswire/ -- Oricell Therapeutics (Oricell), a clinica... | en.prnasia... |
| 01.08.2022 | OriCell Therapeutics Raises Over $120M in Series B Financing | OriCell Therapeutics (Shanghai) Co., Ltd. , a Shangai, China-based developer of novel immunotherapie... | finsmes.co... |
| 01.08.2022 | OriCell Therapeutics Raises Over $120 Million in Series B Fi... | 2022 is set to be a milestone year for OriCell who has been focusing on the field of cancer immunoth... | en.prnasia... |
| - | Oricell Therapeutics | “Primordial Biologics has built four new product research and development technology platforms that ... | fastfounde... |